Cervix Cancer
📧 Sign up to get email alerts when something new happens for Cervix Cancer.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2023-01-09Clinical Trial Update: Fluorescence for Sentinel Lymph Node Identification in Cancer Surgery [Phase 3]
Phase 3 trial update on using fluorescence for sentinel lymph node identification in cancer surgery; completed study.
-
CLINICAL_TRIALS trial_result · 2022-10-20Clinical Trial Update: Optimized Magnetic Resonance Brachytherapy (MR BT) in Cervix Cancer [Phase 2]
Phase 2 clinical trial update on optimized Magnetic Resonance Brachytherapy for cervix cancer completed.
-
CLINICAL_TRIALS trial_result · 2021-12-29Clinical Trial Update: Tisotumab Vedotin (HuMax®-TF-ADC) Safety Study in Patients With Solid Tumors [Phase 1, Phase 2]
Phase 1/2 safety study of tisotumab vedotin (HuMax®-TF-ADC) in patients with solid tumors completed; results posted.
-
CLINICAL_TRIALS trial_result · 2021-11-04Clinical Trial Update: Tisotumab Vedotin Continued Treatment in Patients With Solid Tumors. [Phase 2]
Phase 2 clinical trial update on tisotumab vedotin with continued treatment in patients with various solid tumors, including gynecologic and…
-
CLINICAL_TRIALS trial_result · 2019-09-20Clinical Trial Update: Combination of PD-1 Monoclonal Antibody and HPV Vaccine in Patients With Cervical Cancer [Phase 2]
Phase 2 trial updating combination therapy of a PD-1 monoclonal antibody with an HPV vaccine for cervical cancer.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2019-03-12Clinical Trial Update: Tisotumab Vedotin (HuMax®-TF-ADC) Safety Study in Patients With Solid Tumors [Phase 1, Phase 2]
Phase 1/2 safety study of tisotumab vedotin (HuMax®-TF-ADC) in solid tumors completed; results posted in 2019.
-
CLINICAL_TRIALS trial_result · 2018-08-31Clinical Trial Update: 2D vs 3D Planning for High-Dose Rate (HDR) Gynecological Brachytherapy [Phase 2]
Phase 2 trial comparing 2D versus 3D planning for high-dose-rate gynecological brachytherapy in cervix and endometrial cancer has completed.